{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:35:44Z","timestamp":1762079744168},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In accordance with the 2018 joint consensus document issued by the European Heart Rhythm Association (EHRA), European Society of Cardiology (ESC) Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA), and endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), as well as with other recent ESC Guidelines, the management of antithrombotic therapy of patients with atrial fibrillation undergoing percutaneous coronary intervention requires that multiple and interconnected issues, including, duration of initial triple antithrombotic therapy, selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet therapy, intensity of oral anticoagulation throughout combination therapy, and choice of oral anticoagulant for indefinite therapy, are addressed. To assist the responsible physician in clinical decision making, a series of practical questions are proposed and discussed in the chronological sequence they should likely be answered.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaa047","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T19:58:08Z","timestamp":1588190288000},"page":"68-73","source":"Crossref","is-referenced-by-count":9,"title":["Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence"],"prefix":"10.1093","volume":"7","author":[{"given":"Andrea","family":"Rubboli","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases\u2014AUSL Romagna, Division of Cardiology, Ospedale S. Maria delle Croci, Viale Randi 5, Ravenna 48121, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Swiss Cardiovascular Center, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, A.O.U. Policlinico Vittorio Emanuele, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"2021011615244068300_pvaa047-B1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2021011615244068300_pvaa047-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2021011615244068300_pvaa047-B3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2021011615244068300_pvaa047-B4","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2021011615244068300_pvaa047-B8","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2021011615244068300_pvaa047-B9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"2021011615244068300_pvaa047-B10","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaa003","article-title":"Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations","volume":"6","author":"Rubboli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021011615244068300_pvaa047-B11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ahj.2014.06.016","article-title":"Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin","volume":"168","author":"Baker","year":"2014","journal-title":"Am Heart J"},{"key":"2021011615244068300_pvaa047-B12","doi-asserted-by":"crossref","first-page":"e001026","DOI":"10.1136\/openhrt-2019-001026","article-title":"Performing diagnostic radial access coronary angiography on uninterrupted direct oral anticoagulant therapy: a prospective analysis","volume":"6","author":"Chongprasertpon","year":"2019","journal-title":"Open Heart"},{"key":"2021011615244068300_pvaa047-B13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcin.2016.04.014","article-title":"Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials","volume":"9","author":"Ferrante","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2021011615244068300_pvaa047-B14","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021011615244068300_pvaa047-B15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B17","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","article-title":"Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study","volume":"8","author":"Jackson","year":"2015","journal-title":"ACC Cardiovasc Interv"},{"key":"2021011615244068300_pvaa047-B18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2021011615244068300_pvaa047-B19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2021011615244068300_pvaa047-B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hrthm.2019.07.034","article-title":"Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study","volume":"17","author":"Lau","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021011615244068300_pvaa047-B21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2021011615244068300_pvaa047-B22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"2021011615244068300_pvaa047-B23","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"2021011615244068300_pvaa047-B24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2021011615244068300_pvaa047-B25","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.jcin.2019.08.039","article-title":"Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis","volume":"12","author":"ten Berg","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2021011615244068300_pvaa047-B26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10557-019-06886-w","article-title":"After the AUGUSTUS trial, should apixaban be the only direct oral anticoagulant to be used in triple therapy in atrial fibrillation patients undergoing percutaneous coronary intervention?","volume":"33","author":"Rubboli","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2021011615244068300_pvaa047-B27","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"2021011615244068300_pvaa047-B28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.119.041687","article-title":"Specific antidotes for direct oral anticoagulant reversal: case closed or cold case?","volume":"140","author":"Godier","year":"2019","journal-title":"Circulation"},{"key":"2021011615244068300_pvaa047-B29","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"key":"2021011615244068300_pvaa047-B30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2017.05.016","article-title":"Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: the atrial fibrillation undergoing coronary artery stenting (AFCAS) registry","volume":"190","author":"Proietti","year":"2017","journal-title":"Am Heart J"},{"key":"2021011615244068300_pvaa047-B31","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2019.01.005","article-title":"Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice","volume":"62","author":"Rubboli","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2021011615244068300_pvaa047-B32"},{"key":"2021011615244068300_pvaa047-B33","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021011615244068300_pvaa047-B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial","volume":"360","author":"van Es","year":"2002","journal-title":"Lancet"},{"key":"2021011615244068300_pvaa047-B35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"2021011615244068300_pvaa047-B36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","article-title":"Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease","volume":"64","author":"Hamon","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021011615244068300_pvaa047-B37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"2021011615244068300_pvaa047-B38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa047\/33439138\/pvaa047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/1\/68\/35904846\/pvaa047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/1\/68\/35904846\/pvaa047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:17:42Z","timestamp":1696079862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/1\/68\/5831832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2021,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa047","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,5,7]]}}}